Professor Craddock is interested in the development of clinical treatment of haematological malignancies, key approaches being Stem Cell Transplantation, Donor Lymphocyte Infusion, and also novel chemotherapy regimens. Charlie also has a particular interest in epigenetic modification therapies and their potential to influence anti-tumour immune responses.
Professor of Haemato-oncology, Centre for Clinical Haematology, Queens Elizabeth Hospital.
Background and Research focus
Professor Charlie Craddock is Director of the Blood and Marrow Transplant Unit at the Queen Elizabeth Hospital, Birmingham and Professor of Haemato-oncology at the University of Birmingham. His major areas of clinical interest are the management of myeloid malignancies including Acute Myeloid Leukaemia (AML) and Chronic Myeloid Leukaemia (CML) and he leads an active clinical trials programme devoted to the design of novel drug and transplant therapies in these diseases. He has made substantial contributions to the development of novel reduced intensity conditioning regimens in the treatment of haematological malignancies. In particular, he has overseen one of the first studies of long term outcomes after an alemtuzumab based reduced intensity allograft in AML. He is also examining the clinical activity of these regimens in lymphoma and myeloma. Professor Craddock also has a long-standing interest in the clinical activity of epigenetic drugs in patients with high risk AML. His collaborative studies with Professors Stankovic and Moss has led to clinical trials that reveal that the combined use of epigenetic drugs sodium valproate and 5-azacitide induces anti-tumour CD8+ T-cell responses in patients with AML. This work has culminated in a Phase I/Ii clinical trial which is assessing the clinical activity of post-transplant 5-azacitdine in patients allografted for AML. Professor Craddock has also forged close links with Dr Freeman and Professor Vyas, which has led to tracking of leukaemic stem cell populations by flow cytometry pre and post allogeneic transplantation. This is being further examined in the FIGARO RIC transplantation study and could potentially be used to guide immunotherapeutic interventions.
Haemato-oncology; acute myeloid leukaemia; chronic myeloid leukaemia; epigenetic drugs; reduced intensity conditioning.
Professor Craddock is the Director of the recently established Centre for Clinical Haematology which houses an integrated clinical leukaemia and transplant programme and an early phase trial unit serving one of the largest catchment areas in Europe. More recently he was successful in establishing a national haemato-oncology early phase trials programme called the Therapy Acceleration Programme. This is a strategic initiative to speed up the pace of new clinical trials starting which has been adopted by the LRR. In addition to his clinical research, he has made major contributions to co-ordinating and teaching on various taught programmes at the University of Birmingham. In particular, Charlie is the course organiser of ‘The complete FRCPath’ – a problem orientated postgraduate course for Haematology Specialist Registrars in preparation for the FRCPath exam. Professor Craddock is Chair of UK Stem Cell Strategic Forum which advises the Department of Health on the strategic development of alternative donor stem cell transplantation in the UK. He has also played a leading role in accruing funding for the Institute of Translational Medicine at Birmingham which is due to open in June 2015. This facility will dramatically expand therapeutic options for patients by accelerating access to new diagnostics, drugs and medical devices, placing patients at the core of a uniquely integrated medical campus. Finally, Professor Craddock is the co-founder of the Cure Leukemia charity which was established in 2003.
Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant. 2014 Feb;49(2):280-6.
Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, Morris EC. Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol. 2014 Feb;164(3):366-75.
Cobbold M, De La Pena H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, Craddock C, Williams ME, Hunt DF, Engelhard VH. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med. 2013 Sep 18;5(203):203ra125.
Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivey A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, Brookes C, Davies B, Price A, Wall K, Griffiths M, Cavenagh J, Majeti R, Weissman I, Burnett A, Vyas P. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 2013 Apr;27(5):1028-36.
Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone Marrow Transplant. 2013 Feb;48(2):243-8.
Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, Craddock C, Malladi R, Moss PA. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood. 2012 Nov 15;120(20):4246-55.
Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock CF. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012 Apr 5;119(14):3361-9.
Craddock C. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies. Cytotherapy. 2011 May;13(5):516-7
Craddock, C. Labopin, M. Pillai, S. Finke, J. Bunjes, D. Greinix, H. Ehninger, G. Steckel, NK. Zander, AR. Schwerdtfeger,R. Buchholz, S. Kolb, HJ. Volin, L. Frauser, A. Polge, E. Schmid, C. Mohty, M. Rocha, V. (2011) Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011 Feb 22 [Epub ahead of print]
Goardon, N. Marchi, E. Atzberger, A. Quek, L. Schuh, A. Soneji, S. Woll, P. Mead, A. Alford, KA. Rout, R. Chaudhury,S. Gilkes, A. Knapper,S. Beldjord, K. Begum, S. Rose, S. Geddes, N. Griffiths, M. Standen, G. Sternberg, A. Cavenagh, J. Hunter, H. Bowen, D. Killick, S. Robinson, S. Price, a. Macintyre, E. Virgo, P. Burnett, A. Craddock, C. Enver, T. Jacobsen, SE. Porcher, C. Vyas, P. Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia. Cancer Cell 2011 Jan 18;19(1):138-52.